mTOR inhibitors might have the potential of avoiding these problems Taking our data into consideration, suggestive of an autocrine VEGF-A loop through the AKT/mTOR signalling pathway, this adds preclinical rationale for mTOR inhibition in the management of ovarian cancer. This evidence concerns the gene AKT1 and ovarian carcinoma.